**Cutaneous Oncology**

**Melanoma**

- Unresectable Stage III-IV
  - Any Line
    - Previously treated with anti PD-1
      - MEL0023 Phase III IMO-2125 + ipilimumab vs ipilimumab Alone in Anti-PD-1 Refractory Melanoma
        - PI: Reddy Idera Pharmaceuticals
      - ECOG-ACRIN EA6141 Phase II/III Nivolumab & ipilimumab +/- Sargramostim in Unresectable Unresectable Stage III/IV Melanoma
        - PI: Reddy ECOG-ACRIN

**SKIN0047**
- Phase II Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
  - PI: Knox Stanford

**SKIN0042**
- Phase II INCMGA00012 in Metastatic Merkel Cell Carcinoma
  - PI: Reddy (Pending)

**KEY**

- **Pending**
- **Open for Enrollment**
- **Link**
- **Trial Posting**
- **Extension Study**
- **Immunotherapy**
- **Optional Path**
- **Enrollment on Hold**

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu